HM15136

DRUG3 trials

Sponsors

Hanmi Pharmaceutical Company Limited

Conditions

Congenital HyperinsulinismObese With ComorbiditiesOverweight With ComorbiditiesPharmacologyType2 Diabetes

Phase 1

A First-in-Human, Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HM15136(Efpegerglucagon) in Healthy Subjects

CompletedNCT04032782

Hanmi Pharmaceutical Company LimitedPharmacology

Start: 2018-10-02End: 2019-08-29Updated: 2025-02-05

Study for Multiple Doses of HM15136(Efpegerglucagon) in Obese or Overweight Subjects With Comorbidities

CompletedNCT04167553

Hanmi Pharmaceutical Company LimitedObese With Comorbidities, Overweight With Comorbidities, Type2 Diabetes

Start: 2019-08-30End: 2020-12-09Updated: 2025-01-27

Phase 2

HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI)

Active, not recruitingNCT04732416

Hanmi Pharmaceutical Company LimitedCongenital Hyperinsulinism

Start: 2022-05-05End: 2027-05-01Updated: 2026-08-26

Related Papers

PSUN305 A Double-Blind, Placebo-Controlled Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HM15136 in Obese or Overweight Subjects with Co-morbidities

Journal of the Endocrine Society2022-11-01